|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ettinger DS, Wood DE, Aggarwal C, Aisner
DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac
LR, et al: NCCN guidelines insights: Non-small cell lung cancer,
version 1.2020. J Natl Compr Canc Netw. 17:1464–1472. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosner S, Reuss JE and Forde PM: PD-1
blockade in early-stage lung cancer. Annu Rev Med. 70:425–435.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pastorino U, Buyse M, Friedel G, Ginsberg
RJ, Girard P, Goldstraw P, Johnston M, McCormack P, Pass H and
Putnam JB Jr; International Registry of Lung Metastases, :
Long-term results of lung metastasectomy: Prognostic analyses based
on 5206 cases. J Thorac Cardiovasc Surg. 113:37–49. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu W, Ren Z, Li P, Yu D, Chen J, Huang R
and Liu H: Six1: A critical transcription factor in tumorigenesis.
Int J Cancer. 136:1245–1253. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chu Y, Chen Y, Li M, Shi D, Wang B, Lian
Y, Cheng X, Wang X, Xu M, Cheng T, et al: Six1 regulates leukemia
stem cell maintenance in acute myeloid leukemia. Cancer Sci.
110:2200–2210. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Coletta RD, Christensen KL, Micalizzi DS,
Jedlicka P, Varella-Garcia M and Ford HL: Six1 overexpression in
mammary cells induces genomic instability and is sufficient for
malignant transformation. Cancer Res. 68:2204–2213. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Coletta RD, McCoy EL, Burns V, Kawakami K,
McManaman JL, Wysolmerski JJ and Ford HL: Characterization of the
Six1 homeobox gene in normal mammary gland morphogenesis. BMC Dev
Biol. 10:42010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Wang S, Liu Z, Yang L, Liu J and
Xiu M: Increased Six1 expression in macrophages promotes
hepatocellular carcinoma growth and invasion by regulating MMP-9. J
Cell Mol Med. 23:4523–4533. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang C, Xu W, Gong J, Chai F, Cui D and
Liu Z: Six1 overexpression promotes glucose metabolism and invasion
through regulation of GLUT3, MMP2 and snail in thyroid cancer
cells. Onco Targets Ther. 13:4855–4863. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li L, Liang Y, Kang L, Liu Y, Gao S, Chen
S, Li Y, You W, Dong Q, Hong T, et al: Transcriptional regulation
of the Warburg effect in cancer by SIX1. Cancer Cell.
33:368–385.e7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Q, Li A, Tian Y, Liu Y, Li T, Zhang C,
Wu JD, Han X and Wu K: The expression profile and clinic
significance of the SIX family in non-small cell lung cancer. J
Hematol Oncol. 9:1192016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li N, Yang L, Zhang B and Chen S:
Tanshinone IIA effects on ovarian cancer cell line. J Pharm
Pharmacol. 70:1369–1377. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
International BR: Retracted: Tanshinone
IIA induces apoptosis in human oral cancer KB cells through a
mitochondria-dependent pathway. Biomed Res Int.
2017:94964852017.PubMed/NCBI
|
|
17
|
Chiu SC, Huang SY, Chen SP, Su CC, Chiu TL
and Pang CY: Tanshinone IIA inhibits human prostate cancer cells
growth by induction of endoplasmic reticulum stress in vitro and in
vivo. Prostate Cancer Prostatic Dis. 16:315–322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nie ZY, Zhao MH, Cheng BQ, Pan RF, Wang
TR, Qin Y and Zhang XJ: Tanshinone IIA regulates human AML cell
proliferation, cell cycle, and apoptosis through miR-497-5p/AKT3
axis. Cancer Cell Int. 20:3792020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao F, Li M, Liu W and Li W: Inhibition of
EGFR signaling and activation of mitochondrial apoptosis contribute
to tanshinone IIA-mediated tumor suppression in non-small cell lung
cancer cells. Onco Targets Ther. 13:2757–2769. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liao XZ, Gao Y, Huang S, Chen ZZ, Sun LL,
Liu JH, Chen HR, Yu L, Zhang JX and Lin LZ: Tanshinone IIA combined
with cisplatin synergistically inhibits non-small-cell lung cancer
in vitro and in vivo via down-regulating the phosphatidylinositol
3-kinase/Akt signalling pathway. Phytother Res. 33:2298–2309. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie J, Liu J, Liu H, Liang S, Lin M, Gu Y,
Liu T, Wang D, Ge H and Mo SL: The antitumor effect of tanshinone
IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on
the human non-small cell lung cancer A549 cell line. Acta Pharm Sin
B. 5:554–563. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang X and Xu R: Six1 expression is
associated with a poor prognosis in patients with glioma. Oncol
Lett. 13:1293–1298. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chassagnon G, Bennani S and Revel MP: New
TNM classification of non-small cell lung cancer. Rev Pneumol Clin.
73:34–39. 2017.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yen JH, Huang ST, Huang HS, Fong YC, Wu
YY, Chiang JH and Su YC: HGK-sestrin 2 signaling-mediated autophagy
contributes to antitumor efficacy of Tanshinone IIA in human
osteosarcoma cells. Cell Death Dis. 9:10032018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chao L, Liu J and Zhao D: Increased Six1
expression is associated with poor prognosis in patients with
osteosarcoma. Oncol Lett. 13:2891–2896. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li W, Qin Y, Zhou R, Liu Y and Zhang G:
High expression of SIX1 is an independent predictor of poor
prognosis in endometrial cancer. Am J Transl Res. 13:2840–2848.
2021.PubMed/NCBI
|
|
28
|
Bose S and Le A: Glucose metabolism in
cancer. Adv Exp Med Biol. 1063:3–12. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luengo A, Gui DY and Vander Heiden MG:
Targeting metabolism for cancer therapy. Cell Chem Biol.
24:1161–1180. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pascale RM, Calvisi DF, Simile MM, Feo CF
and Feo F: The Warburg effect 97 years after its discovery. Cancers
(Basel). 12:28192020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vaupel P, Schmidberger H and Mayer A: The
Warburg effect: Essential part of metabolic reprogramming and
central contributor to cancer progression. Int J Radiat Biol.
95:912–919. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ishibashi K, Egami R, Nakai K and Kon S:
An anti-tumorigenic role of the Warburg effect at emergence of
transformed cells. Cell Struct Funct. 43:171–176. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bar-Or D, Carrick M, Tanner A II, Lieser
MJ, Rael LT and Brody E: Overcoming the Warburg effect: Is it the
key to survival in sepsis? J Crit Care. 43:197–201. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Z, Zhang Y, Zhou Y, Wang F, Yin C, Ding
L and Zhang S: Tanshinone IIA suppresses the progression of lung
adenocarcinoma through regulating CCNA2-CDK2 complex and AURKA/PLK1
pathway. Sci Rep. 11:236812021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu Z, Zhu W, Kong X, Chen X, Sun X, Zhang
W and Zhang R: Tanshinone IIA inhibits glucose metabolism leading
to apoptosis in cervical cancer. Oncol Rep. 42:1893–1903.
2019.PubMed/NCBI
|
|
36
|
Li M, Gao F, Zhao Q, Zuo H, Liu W and Li
W: Tanshinone IIA inhibits oral squamous cell carcinoma via
reducing Akt-c-Myc signaling-mediated aerobic glycolysis. Cell
Death Dis. 11:3812020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang HS, Zhang FJ, Li H, Liu Y, Du GY and
Huang YH: Tanshinone IIA inhibits human esophageal cancer cell
growth through miR-122-mediated PKM2 down-regulation. Arch Biochem
Biophys. 598:50–56. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nie ZY, Liu XJ, Zhan Y, Liu MH, Zhang XY,
Li ZY, Lu YQ, Luo JM and Yang L: miR-140-5p induces cell apoptosis
and decreases Warburg effect in chronic myeloid leukemia by
targeting SIX1. Biosci Rep. 39:BSR201901502019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang H, Xue W, Ouyang W and Jiang X and
Jiang X: miR-23a-3p/SIX1 regulates glucose uptake and proliferation
through GLUT3 in head and neck squamous cell carcinomas. J Cancer.
11:2529–2539. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou H, Blevins MA, Hsu JY, Kong D,
Galbraith MD, Goodspeed A, Culp-Hill R, Oliphant MUJ, Ramirez D,
Zhang L, et al: Identification of a small-molecule inhibitor that
disrupts the SIX1/EYA2 complex, EMT, and metastasis. Cancer Res.
80:2689–2702. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chu Y, Jiang M, Wu N, Xu B, Li W, Liu H,
Su S, Shi Y, Liu H, Gao X, et al: O-GlcNAcylation of SIX1 enhances
its stability and promotes hepatocellular carcinoma proliferation.
Theranostics. 10:9830–9842. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sui H, Zhao J, Zhou L, Wen H, Deng W, Li
C, Ji Q, Liu X, Feng Y, Chai N, et al: Tanshinone IIA inhibits
β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in
normoxic and HIF-1α in hypoxic microenvironments in human
colorectal cancer. Cancer Lett. 403:86–97. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li G, Shan C, Liu L, Zhou T, Zhou J, Hu X,
Chen Y, Cui H and Gao N: Tanshinone IIA inhibits HIF-1α and VEGF
expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1
signaling pathway. PLoS One. 10:e01174402015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zeng J, Shi R, Cai CX, Liu XR, Song YB,
Wei M and Ma WL: Increased expression of Six1 correlates with
progression and prognosis of prostate cancer. Cancer Cell Int.
15:632015. View Article : Google Scholar : PubMed/NCBI
|
